UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk

Journal of clinical oncology, 2022-06, Vol.40 (16), p.1713-1717

2022

Volltextzugriff (PDF)

Outcome of Head Start III multinational protocol for newly diagnosed central nervous system (CNS) primitive neuroectodermal tumors (pnet) of young children

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.9519-9519

2011

Volltextzugriff (PDF)

Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.2011-2011

2011

Volltextzugriff (PDF)

Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

Journal of clinical oncology, 2013-11, Vol.31 (31), p.3971-3979

2013

Volltextzugriff (PDF)

Words Matter

Journal of clinical oncology, 2023-01, Vol.41 (3), p.706-707

2023

Volltextzugriff (PDF)

Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5044-5044

2022

Volltextzugriff (PDF)

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.363-363

2024

Volltextzugriff (PDF)

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.LBA358-LBA358

2024

Volltextzugriff (PDF)

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.TPS403-TPS403

2022

Volltextzugriff (PDF)

From the lab to the clinic: Lessons learned from a translational working group

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e12576-e12576

2023

Volltextzugriff (PDF)

A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2070-2070

2019

Volltextzugriff (PDF)

Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.491-491

2022

Volltextzugriff (PDF)

Loss of MDA-7 expression with progression of melanoma

Journal of clinical oncology, 2002-02, Vol.20 (4), p.1069-1074

2002

Volltextzugriff (PDF)

Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients

Journal of clinical oncology, 1997-08, Vol.15 (8), p.2826-2831

1997

Volltextzugriff (PDF)

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.609-609

2020

Volltextzugriff (PDF)

Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214)

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.686-686

2018

Volltextzugriff (PDF)

HER2 testing: Insights from pathologists’ perspective on challenging HER2 cases

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12512-e12512

2019

Volltextzugriff (PDF)

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3073-3073

2018

Volltextzugriff (PDF)

Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.690-690

2020

Volltextzugriff (PDF)

Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.687-687

2020

Volltextzugriff (PDF)

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.581-581

2019

Volltextzugriff (PDF)

Loss of MDA-7 Expression With Progression of Melanoma

Journal of clinical oncology, 2002-02, Vol.20 (4), p.1069-1074

Ellerhorst, J. A.

2002

Volltextzugriff (PDF)

A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2061-2061

2015

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)

Erscheinungsjahr

n.n

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk

Outcome of Head Start III multinational protocol for newly diagnosed central nervous system (CNS) primitive neuroectodermal tumors (pnet) of young children

Outcome of infants and young children with newly diagnosed medulloblastoma treated on Head Start III protocol

Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome

Words Matter

Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS

Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial

Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial

Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial

PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC)

From the lab to the clinic: Lessons learned from a translational working group

A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT)

Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score

Loss of MDA-7 expression with progression of melanoma

Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients

Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)

Characterization of the benefit-risk profile of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced renal cell carcinoma (aRCC; CheckMate 214)

HER2 testing: Insights from pathologists’ perspective on challenging HER2 cases

Quality of life in patients with advanced renal cell carcinoma in the randomized, open-label CheckMate 214 trial

Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101

Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S)

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214

Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214

Loss of MDA-7 Expression With Progression of Melanoma

A phase I trial everolimus and sorafenib in patients with recurrent high-grade gliomas: Brain Tumor Treatment Collaborative trial 09-01

Aktive Filter

Suchergebnisse filtern